News Column

Studies from University of North Carolina Yield New Information about Melanomas

February 14, 2014



By a News Reporter-Staff News Editor at Drug Week -- Data detailed on Melanomas have been presented. According to news originating from Chapel Hill, North Carolina, by NewsRx correspondents, research stated, "Immunotherapy has shown the potential to become an essential component of the successful treatment of various malignancies. In many cases, such as in melanoma, however, induction of a potent and specific T-cell response against the endogenous antigen or self-antigen still remains a major challenge."

Our news journalists obtained a quote from the research from the University of North Carolina, "To induce a potent MHC I-restricted cytotoxic T-lymphocyte (CTL) response, cytosol delivery of an exogenous antigen into dendritic cells is preferred, if not required. Lipid-calcium-phosphate (LCP) nanoparticles represent a new class of intracellular delivery systems for impermeable drugs. We are interested in exploring the potential of LCP NPs for use as a peptide vaccine delivery system for cancer therapy. To increase the encapsulation of Trp2 peptide into the calcium phosphate precipitate core of LCP, two phosphor-serine residues were added to the N-terminal of the peptide (p-Trp2). CpG ODN was also co-encapsulated with p-Trp2 as an adjuvant. The NPs were further modified with mannose to enhance and prolong the cargo deposit into the lymph nodes (LNs), which ensured persistent antigen loading and stimulation. Compared with free Trp2 peptide/CpG, vaccination with LCP encapsulating p-Trp2 and CpG resulted in superior inhibition of tumor growth in both B16F10 subcutaneous and lung metastasis models. An IFN-gamma production assay and in vivo CTL response study revealed that the improved efficacy was a result of a Trp2-specific immune response."

According to the news editors, the research concluded: "Thus, encapsulation of phospho-peptide antigens into LCP may be a promising strategy for enhancing the immunogenicity of poorly immunogenic self-antigens for cancer therapy."

For more information on this research see: Multifunctional nanoparticles co-delivering Trp2 peptide and CpG adjuvant induce potent cytotoxic T-lymphocyte response against melanoma and its lung metastasis. Journal of Controlled Release, 2013;172(1):259-265. Journal of Controlled Release can be contacted at: Elsevier Science Bv, PO Box 211, 1000 Ae Amsterdam, Netherlands. (Elsevier - www.elsevier.com; Journal of Controlled Release - www.elsevier.com/wps/product/cws_home/502690)

The news correspondents report that additional information may be obtained from Z.H. Xu, University of North Carolina, Eshelman Sch Pharm, Div Mol Pharmaceut, Center Nanotechnol Drug Delivery, Chapel Hill, NC 27599, United States. Additional authors for this research include S. Ramishetti, Y.C. Tseng, S.T. Guo, Y.H. Wang and L. Huang (see also Melanomas).

Keywords for this news article include: Antigens, Melanomas, Immunology, Chapel Hill, Blood Cells, Nanoparticle, United States, Immunotherapy, North Carolina, Nanotechnology, Cancer Vaccines, Immunomodulation, Biological Factors, Emerging Technologies, Mononuclear Leukocytes, Cytotoxic T-Lymphocytes, Hemic and Immune Systems, North and Central America

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC


For more stories covering the world of technology, please see HispanicBusiness' Tech Channel



Source: Drug Week


Story Tools